NASDAQ:RAPT RAPT Therapeutics (RAPT) Stock Price, News & Analysis → 1970’s computer coder Issues Shocking AI Warning (From InvestorPlace) (Ad) Free RAPT Stock Alerts Notice: Trading of RAPT Therapeutics halted at 10:00 AM EST due to "LULD pause". $4.66 -3.32 (-41.60%) (As of 05:13 PM ET) Add Compare Share Share Today's Range$4.39▼$6.0550-Day Range$7.70▼$9.3852-Week Range$4.39▼$27.35Volume4.85 million shsAverage Volume1.14 million shsMarket Capitalization$162.17 millionP/E RatioN/ADividend YieldN/APrice Target$25.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get RAPT Therapeutics alerts: Email Address RAPT Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside450.8% Upside$25.67 Price TargetShort InterestBearish9.14% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.19) to ($2.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.92 out of 5 starsMedical Sector198th out of 915 stocksPharmaceutical Preparations Industry77th out of 426 stocks 4.3 Analyst's Opinion Consensus RatingRAPT Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageRAPT Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about RAPT Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.14% of the outstanding shares of RAPT Therapeutics have been sold short.Short Interest Ratio / Days to CoverRAPT Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RAPT Therapeutics has recently increased by 6.71%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRAPT Therapeutics does not currently pay a dividend.Dividend GrowthRAPT Therapeutics does not have a long track record of dividend growth. Previous Next 3.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRAPT Therapeutics has received a 44.02% net impact score from Upright. Rapt Therapeutics seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for RAPT Therapeutics is -0.81. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for RAPT Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for RAPT on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows3 people have added RAPT Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RAPT Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of RAPT Therapeutics is held by insiders.Percentage Held by Institutions99.09% of the stock of RAPT Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about RAPT Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for RAPT Therapeutics are expected to grow in the coming year, from ($3.19) to ($2.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RAPT Therapeutics is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RAPT Therapeutics is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRAPT Therapeutics has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about RAPT Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceProof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…Go here now for full story. About RAPT Therapeutics Stock (NASDAQ:RAPT)RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanyRead More RAPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RAPT Stock News HeadlinesMay 9, 2024 | investorplace.comRAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024May 9, 2024 | globenewswire.comRAPT Therapeutics Reports First Quarter 2024 Financial ResultsMay 9, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.April 29, 2024 | americanbankingnews.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of "Moderate Buy" by AnalystsApril 12, 2024 | markets.businessinsider.comHold Rating on RAPT Therapeutics Amid Promising Data and Regulatory UncertaintiesApril 11, 2024 | investing.comRAPT reports positive phase 2 cancer trial resultsApril 10, 2024 | markets.businessinsider.comMaintaining Hold Rating on RAPT Therapeutics Amidst Mixed Clinical Results and Regulatory UncertaintyApril 9, 2024 | globenewswire.comRAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer PatientsMay 9, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.April 9, 2024 | investorplace.com3 Biotech Stocks to Dump Before They Go to ZeroMarch 16, 2024 | finance.yahoo.comRAPT Apr 2024 10.000 putMarch 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTMarch 11, 2024 | markets.businessinsider.comHold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial ConcernsMarch 8, 2024 | finance.yahoo.comRAPT Oct 2024 5.000 callMarch 7, 2024 | investorplace.comRAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023March 7, 2024 | globenewswire.comRAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 5, 2024 | globenewswire.comRAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual MeetingMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTFebruary 26, 2024 | businesswire.comRAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsFebruary 23, 2024 | finance.yahoo.comRAPT May 2024 17.500 putFebruary 22, 2024 | msn.comUBS Downgrades RAPT Therapeutics (RAPT)February 21, 2024 | msn.comHC Wainwright & Co. Downgrades RAPT Therapeutics (RAPT)February 21, 2024 | msn.comLeerink Partners Downgrades RAPT Therapeutics (RAPT)February 21, 2024 | realmoney.thestreet.comRapt Therapeutics just downgraded at Leerink, here's whyFebruary 21, 2024 | msn.comJ.P. Morgan cuts RAPT to neutral, recommends against buying dipFebruary 21, 2024 | msn.comH.C. Wainwright cuts RAPT to neutral, cites delays due to clinical holdFebruary 21, 2024 | markets.businessinsider.comWhat's Going On With RAPT Therapeutics Stock On Wednesday?See More Headlines Receive RAPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/09/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RAPT CUSIPN/A CIK1673772 Webwww.rapt.com Phone(650) 489-9000FaxN/AEmployees131Year Founded2015Price Target and Rating Average Stock Price Target$25.67 High Stock Price Target$41.00 Low Stock Price Target$10.00 Potential Upside/Downside+221.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-63.14% Return on Assets-55.48% Debt Debt-to-Equity RatioN/A Current Ratio7.41 Quick Ratio7.41 Sales & Book Value Annual Sales$1.53 million Price / Sales181.51 Cash FlowN/A Price / Cash FlowN/A Book Value$4.27 per share Price / Book1.87Miscellaneous Outstanding Shares34,800,000Free Float32,503,000Market Cap$277.70 million OptionableOptionable Beta0.52 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Brian Russell Wong M.D. (Age 52)Ph.D., CEO, President & Director Comp: $861.24kMr. Rodney K. B. Young (Age 61)CFO, Principal Accounting Officer & Secretary Comp: $616.56kDr. William Ho M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $620.32kSteve Young Ph.D.Vice President of TechnologyDr. Dirk G. Brockstedt Ph.D. (Age 55)Chief Scientific Officer Comp: $490.25kMr. Michael ListgartenGeneral CounselMs. Gwen R. Carscadden (Age 63)Chief Human Resources Officer Dr. Paul Kassner (Age 57)Senior Vice President of Quantitative & Computational Biology Dr. David Wustrow (Age 65)Senior Vice President of Drug Discovery & Preclinical Development Ms. Jennifer NicholsonSenior Vice President of Regulatory Affairs & Quality AssuranceMore ExecutivesKey CompetitorsXBiotechNASDAQ:XBITEliem TherapeuticsNASDAQ:ELYMXeris BiopharmaNASDAQ:XERSInozyme PharmaNASDAQ:INZYCytomX TherapeuticsNASDAQ:CTMXView All CompetitorsInsiders & InstitutionsMirae Asset Global Investments Co. Ltd.Sold 7,956 shares on 5/1/2024Ownership: 0.036%China Universal Asset Management Co. Ltd.Bought 2,621 shares on 4/29/2024Ownership: 0.019%Denali Advisors LLCBought 32,600 shares on 4/19/2024Ownership: 0.094%Los Angeles Capital Management LLCBought 41,516 shares on 4/5/2024Ownership: 0.146%Kingdon Capital Management L.L.C.Bought 160,000 shares on 3/18/2024Ownership: 2.775%View All Insider TransactionsView All Institutional Transactions RAPT Stock Analysis - Frequently Asked Questions Should I buy or sell RAPT Therapeutics stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RAPT shares. View RAPT analyst ratings or view top-rated stocks. What is RAPT Therapeutics' stock price target for 2024? 12 brokers have issued 12-month price objectives for RAPT Therapeutics' stock. Their RAPT share price targets range from $10.00 to $41.00. On average, they predict the company's stock price to reach $25.67 in the next twelve months. This suggests a possible upside of 450.8% from the stock's current price. View analysts price targets for RAPT or view top-rated stocks among Wall Street analysts. How have RAPT shares performed in 2024? RAPT Therapeutics' stock was trading at $24.85 on January 1st, 2024. Since then, RAPT shares have decreased by 81.2% and is now trading at $4.66. View the best growth stocks for 2024 here. When is RAPT Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our RAPT earnings forecast. How were RAPT Therapeutics' earnings last quarter? RAPT Therapeutics, Inc. (NASDAQ:RAPT) posted its quarterly earnings data on Thursday, March, 7th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.05. What ETFs hold RAPT Therapeutics' stock? ETFs with the largest weight of RAPT Therapeutics (NASDAQ:RAPT) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). What is Brian Wong's approval rating as RAPT Therapeutics' CEO? 8 employees have rated RAPT Therapeutics Chief Executive Officer Brian Wong on Glassdoor.com. Brian Wong has an approval rating of 100% among the company's employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of RAPT Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA), Boeing (BA), Slack Technologies (WORK), Overstock.com (OSTK), Salesforce (CRM), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Livongo Health (LVGO), Mastercard (MA) and QUALCOMM (QCOM). When did RAPT Therapeutics IPO? RAPT Therapeutics (RAPT) raised $39 million in an initial public offering on Thursday, October 31st 2019. The company issued 3,000,000 shares at a price of $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank served as the underwriters for the IPO. Who are RAPT Therapeutics' major shareholders? RAPT Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.15%), Denali Advisors LLC (0.09%), Mirae Asset Global Investments Co. Ltd. (0.04%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Dirk G Brockstedt, Dirk G Brockstedt, Gino Dellomo, Group Ii Lp Column, Phuong Y Phillips, Rodney Kb Young, Wendye Robbins and William Ho. View institutional ownership trends. How do I buy shares of RAPT Therapeutics? Shares of RAPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RAPT) was last updated on 5/9/2024 by MarketBeat.com Staff From Our Partners1970’s computer coder Issues Shocking AI WarningInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersObama’s Forever Term [exposed]Porter & Company348 million Americans lives to END as we know it?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RAPT Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.